FDA Decision on Liso-cel, CAR T-cell Therapy for Large B-cell Lymphoma, Due in November
News
The U.S. Food and Drug Administration (FDA) has extended by three months its review of Bristol-Myers Squibb’s investigational CAR T-cell therapy, lisocabtagene maraleucel (liso-cel), as a treatment for adults with relapsed or refractory large B-cell lymphoma after at ... Read more